APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Core Insights - Apogee Therapeutics (APGE) shares increased by 20% following the announcement of positive 52-week maintenance data for zumilokibart (APG777), an anti-IL-13 antibody for moderate-to-severe atopic dermatitis [1][6]. Study Details - Part A of the phase II APEX clinical study involved 123 adult patients, randomized in a 2:1 ratio to receive either zumilokibart or placebo, with an induction regimen of 720 mg at weeks 0 and 2, followed by 360 mg at weeks 4 and 12 [2]. - The study demonstrated a 71% reduction in the Eczema Area Severity Index (EASI) at 16 weeks for zumilokibart compared to 33.8% for placebo, achieving a best-in-class EASI-75 response of 66.9% versus 24.6% for placebo [3]. Efficacy and Safety - Key secondary endpoints showed favorable results, including a Validated Investigator's Global Assessment (vIGA) 0/1 of 34.9% for zumilokibart compared to 17.3% for placebo, and EASI-90 responses of 33.9% versus 14.7% [4]. - Zumilokibart provided rapid itch relief, with significant improvements noted as early as Week 1, and exhibited a favorable safety profile with mostly mild to moderate adverse events [4][10]. Long-term Efficacy - The 52-week results indicated sustained efficacy, with EASI-75 responses maintained in 75% and 85% of patients on three and six-month regimens, respectively [8]. - Incremental gains were observed in the broader study population, suggesting that extended therapy may enhance outcomes even for slower responders [9]. Future Development - Apogee Therapeutics plans to initiate phase III development of zumilokibart in the second half of 2026, with Part B 16-week data expected in Q2 2026 [6][13].